Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
EUCRW was delisted on the 26th of April, 2023.
26 hedge funds and large institutions have $1.09M invested in Eucrates Biomedical Acquisition Corp. Warrant in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
58% more capital invested
Capital invested by funds: $691K → $1.09M (+$403K)
8% more funds holding
Funds holding: 24 → 26 (+2)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Arena Investors
Purchase,
New York
|
+$15.2K |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10.7K |
| 3 |
SC
Sculptor Capital
New York
|
+$4.24K |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.21K |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$3.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$10.4K |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$6K |
| 3 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$5K |
| 4 |
GCL
Glazer Capital LLC
New York
|
-$1.37K |
| 5 |
Goldman Sachs
New York
|
-$1.03K |
EUCRW Hedge Fund Activity: Q2 2022 in Review
26 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) for Q2 2022, worth a combined $1.09M — up 58% from $691K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EUCRW positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Arena Investors, opening a new position worth an estimated $15.2K. The largest seller was Cowen and Company, cutting an estimated $10.4K.
- 26 institutional investors held Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) as of Q2 2022, up from 24 in Q1 2022.
- Funds reported $1.09M of Eucrates Biomedical Acquisition Corp. Warrant stock for Q2 2022, up 58% quarter-over-quarter.
- 5 funds opened new Eucrates Biomedical Acquisition Corp. Warrant positions in Q2 2022 and 3 closed out, a net change of +2 holders.
- The largest Eucrates Biomedical Acquisition Corp. Warrant buyer in Q2 2022 was Arena Investors, an estimated $15.2K added.
- The largest Eucrates Biomedical Acquisition Corp. Warrant seller in Q2 2022 was Cowen and Company, an estimated $10.4K sold.
Based on aggregated 13F filings for Q2 2022.